Baird analyst Mircea Dobre maintains Oshkosh (NYSE:OSK) with a Neutral and lowers the price target from $84 to $83.
British Agency Supports Eli Lilly’s Weight Loss Drug Mounjaro, Diverging From Restrictions on Rival Novo Nordisk’s Wegovy
NICE recommends Eli Lilly's Mounjaro for obesity, omitting time limits applied to Novo Nordisk's Wegovy, opening new avenues for long-term treatment.